Lurbinectedin Is Safe and Active in Relapsed Small-Cell Lung Cancer

Article navigation

Research Watch| June 01 2020

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2020

American Association for Cancer Research.

Cancer Discov (2020) 10 (6): 757.

Abstract

Lurbinectedin produced responses in 35.2% of 105 patients with relapsed small-cell lung cancer.

2020

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.